简介：【摘要】目的：分析慢性便秘患者结肠镜检查前肠道准备不合格的影响因素，并且提出护理慢性便秘患者的策略。方法：于2021年1月-2022年1月时间段内，选择128例我院接收的慢性便秘患者，作为本次研究的对象。通过分析患者肠道准备不合格情况，获得研究结果。结果：128例患者中，不合格发生率为23.4%（30/128）。多因素分析结果显示，年龄＞60岁、服药期间活动不足以及糖尿病史都是肠道准备不合格的独立为欸先因素，P＜0.05。结论：从肠镜检查前肠道准备不达标的原因分析，主要包括高龄和服药期间活动不足等，影响到肠镜检查的效果，需强化护理质量，提高患者肠道准备的合格率。

简介：　　 [摘要 ] 目的 探讨美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的疗效及其对炎性因子的影响。 方法 选取 2018年 1月～ 2020年 1月我院收治的溃疡性结肠炎患者 80例，随机分为两组，每组各 40例，两组患者均予常规对症治疗，同时两组均予美沙拉嗪缓释颗粒，观察组同时加用双歧三联活菌胶囊，治疗后比较两组患者治疗后的临床疗效，以及两组患者治疗前后 TNF-α、 IL-10水平的变化情况及两组患者治疗前后的临床症状积分变化情况。结果 观察组治疗后的总有效率为 95.00%，显著高于对照组的总有效率 70.00%，两组疗效比较差异具有显著性（ P<0.05）。治疗后，两组患者的炎性因子 TNF-α、 IL-10水平较治疗前显著降低（ P<0.05）。且观察组患者治疗后的 TNF-α、 IL-10水平显著低于对照组（ P<0.05）。观察组患者治疗后的临床症状积分为（ 2.56±0.85）分，与治疗前及对照组比较，差异有统计学意义（ P<0.05）。 结论 美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎疗效确切，且可以抑制炎症反应，值得临床推广和应用。  　　 [关键词 ] 溃疡性结肠炎 ;美沙拉嗪 ;双歧三联活菌 ;炎性因子  　 [Abstract] Objective To investigate the efficacy of mesalazine combined with Bifid Triple Viable Bacteria in the treatment of ulcerative colitis and its influence on inflammatory factors. method Methods: 80 patients with ulcerative colitis in our hospital from January 2018 to January 2020 were selected and randomly divided into two groups, 40 cases in each group. Both groups were given conventional symptomatic treatment, while the two groups were given mesalazine sustained-release granules. The observation group was also given Bifid Triple Viable capsules. After treatment, the clinical efficacy of the two groups of patients after treatment, as well as TNF - α, IL-10 water before and after treatment, were compared between the two groups The changes of the two groups of patients before and after treatment of clinical symptoms integral changes. Results the total effective rate of the observation group was 95.00%, which was significantly higher than that of the control group (70.00%). There was a significant difference between the two groups (P < 0.05). After treatment, the levels of inflammatory factors TNF - α and IL-10 in the two groups were significantly lower than those before treatment (P < 0.05). The levels of TNF - α and IL-10 in the observation group were significantly lower than those in the control group (P < 0.05). The clinical symptom score of the observation group after treatment was (2.56 ± 0.85), and the difference was statistically significant (P < 0.05). Conclusion mesalazine combined with Bifid Triple Viable Bacteria is effective in the treatment of ulcerative colitis, and can inhibit inflammatory reaction, which is worthy of clinical promotion and application.